Published in Medical Letter on the CDC and FDA, March 12th, 2006
The study was previously approved by the responsible Ethics Committee of Heidelberg University Hospital.
Enecadin is a neuroprotective sodium and calcium channel blocker. It has been extensively studied in various in vivo models examining pharmacokinetic and pharmacodynamic parameters and with respect to safety and toxicity. It has shown excellent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.